Here are three things to know:
1. The strategic partnership for the nonexclusive worldwide distribution of the mesenchymal cells will allow BI-USA to bring full cell culture solutions to its customers.
2. StemExpress uses proprietary technology to readily expanded BM-MSCs from healthy donors.
3. StemExpress, BI-USA and partner labs have evaluated the performance of StemExpress Human BM-MSCs in combination with BI-USA’s NutriStem MSC Medium. Itdemonstrated improved MSC expansion compared to industry-standard MSC culture conditions.
More articles on biologics:
Burst Biologics’ umbilical cord blood-derived product is a promising option for spinal fusion, study finds
Orthobiologics market to reach $10.1B by 2025 — 6 key market players
Regenerative medicine company names Susan Vogt to board of directors: 3 notes
